Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
421 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape. MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 12, 72, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 22 molecules, respectively.Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Overview 8 Therapeutics Development 9 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics under Development by Companies 11 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 18 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Products Glance 20 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Products under Development by Companies 24 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 33 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development 36 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment 126 Drug Profiles 138 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects 380 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products 388 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones 389 Appendix 401
List of Tables
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2016 28 Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis, H2 2016 29 Number of Products under Development by Companies, H2 2016 30 Number of Products under Development by Companies, H2 2016 (Contd..1) 31 Number of Products under Development by Companies, H2 2016 (Contd..2) 32 Number of Products under Development by Companies, H2 2016 (Contd..3) 33 Number of Products under Development by Companies, H2 2016 (Contd..4) 34 Number of Products under Development by Companies, H2 2016 (Contd..5) 35 Number of Products under Development by Companies, H2 2016 (Contd..6) 36 Number of Products under Investigation by Universities/Institutes, H2 2016 37 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 38 Comparative Analysis by Late Stage Development, H2 2016 39 Comparative Analysis by Clinical Stage Development, H2 2016 40 Comparative Analysis by Early Stage Development, H2 2016 41 Comparative Analysis by Unknown Stage Development, H2 2016 42 Products under Development by Companies, H2 2016 43 Products under Development by Companies, H2 2016 (Contd..1) 44 Products under Development by Companies, H2 2016 (Contd..2) 45 Products under Development by Companies, H2 2016 (Contd..3) 46 Products under Development by Companies, H2 2016 (Contd..4) 47 Products under Development by Companies, H2 2016 (Contd..5) 48 Products under Development by Companies, H2 2016 (Contd..6) 49 Products under Development by Companies, H2 2016 (Contd..7) 50 Products under Development by Companies, H2 2016 (Contd..8) 51 Products under Investigation by Universities/Institutes, H2 2016 52 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 53 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 54 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Limited, H2 2016 55 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Ltd, H2 2016 56 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H2 2016 57 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AIMM Therapeutics B.V., H2 2016 58 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Limited, H2 2016 59 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H2 2016 60 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AlphaMab Co., Ltd, H2 2016 61 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alvogen Korea Co., Ltd., H2 2016 62 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2016 63 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AnGes MG, Inc., H2 2016 64 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Antibiotx ApS, H2 2016 65 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corporation, H2 2016 66 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 67 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Arsanis, Inc., H2 2016 68 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AstraZeneca Plc, H2 2016 69 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Atriva Therapeutics GmbH, H2 2016 70 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H2 2016 71 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech International Limited, H2 2016 72 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3 Jian, Inc, H2 2016 73 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellceutix Corporation, H2 2016 74 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cempra Inc, H2 2016 75 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals, Inc., H2 2016 76 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Common Pharma Inc, H2 2016 77 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corporation, H2 2016 78 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone, Inc., H2 2016 79 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Critical Outcome Technologies Inc, H2 2016 80 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics, Inc., H2 2016 81 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CSA Biotechnologies LLC , H2 2016 82 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA , H2 2016 83 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dermala Inc, H2 2016 84 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix, Inc., H2 2016 85 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Limited, H2 2016 86 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 87 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by e-Therapeutics Plc, H2 2016 88 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc., H2 2016 89 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ensol Biosciences Inc., H2 2016 90 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Excelimmune, Inc., H2 2016 91 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galapagos NV, H2 2016 92 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc., H2 2016 93 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Gero Corp, H2 2016 94 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix, Inc., H2 2016 95 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016 96 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2016 97 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Immupharma Plc, H2 2016 98 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc., H2 2016 99 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics, Inc., H2 2016 100 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 101 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lascco SA, H2 2016 102 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences, Inc, H2 2016 103 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lipocure Ltd., H2 2016 104 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics B.V., H2 2016 105 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics, Inc, H2 2016 106 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co., Inc., H2 2016 107 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix, Inc., H2 2016 108 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016 109 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MorphoSys AG, H2 2016 110 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Motif Bio Plc, H2 2016 111 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics AG, H2 2016 112 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience, Inc., H2 2016 113 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novabiotics Limited, H2 2016 114 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics, Inc., H2 2016 115 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 116 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Omnia Molecular Ltd., H2 2016 117 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oragenics, Inc., H2 2016 118 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pfizer Inc., H2 2016 119 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Phico Therapeutics Limited, H2 2016 120 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Procarta Biosystems Limited, H2 2016 121 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Prommune, Inc., H2 2016 122 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Recce Pty Ltd, H2 2016 123 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Redx Pharma Plc, H2 2016 124 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016 125 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Savara Inc., H2 2016 126 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 127 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2016 128 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sequoia Sciences Inc, H2 2016 129 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix, Inc., H2 2016 130 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics Inc, H2 2016 131 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co., Ltd., H2 2016 132 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2016 133 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC, H2 2016 134 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 135 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TGV-Laboratories, H2 2016 136 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma Inc, H2 2016 137 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience, Inc., H2 2016 138 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Limited, H2 2016 139 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech, Inc., H2 2016 140 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wintermute Biomedical LLC, H2 2016 141 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Limited, H2 2016 142 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech Inc, H2 2016 143 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 144 Assessment by Monotherapy Products, H2 2016 145 Assessment by Combination Products, H2 2016 146 Number of Products by Stage and Target, H2 2016 148 Number of Products by Stage and Mechanism of Action, H2 2016 151 Number of Products by Stage and Route of Administration, H2 2016 154 Number of Products by Stage and Molecule Type, H2 2016 156 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2016 399 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..1), H2 2016 400 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..2), H2 2016 401 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..3), H2 2016 402 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..4), H2 2016 403 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..5), H2 2016 404 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..6), H2 2016 405 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..7), H2 2016 406 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, H2 2016 407
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
